The Avience Biomedicals IPO is set to open on 18 June 2026, attracting investors looking for opportunities in India's rapidly growing diagnostics and biotechnology sector. The company operates in the biotechnology, genomics, and IVD (In-Vitro Diagnostics) segment and manufactures a wide range of molecular diagnostic and medical products.
In this article, we will cover the Avience Biomedicals IPO GMP issue details, financials, strengths, risks, subscription details, and whether investors should apply for this SME IPO
About Avience Biomedicals Limited
Avience Biomedicals Limited is an ISO-certified healthcare company engaged in biotechnology, genomics, and the In-Vitro Diagnostics (IVD) industry. The company manufactures, supplies, exports, and trades diagnostic products and medical devices catering to hospitals, pathology laboratories, microbiology labs, and research institutions.
Product Portfolio
Rapid Test Kits
Molecular Diagnostics
Biochemistry Reagents and Analyzers
Hematology Analyzers
Medical Equipment
Serology Products
The company serves both B2B and B2G segments and is steadily expanding its domestic and international presence.
Avience Biomedicals IPO GMP Today
As of 15 June 2026, the Avience Biomedicals IPO GMP (Grey Market Premium) stands at ₹40 per share.
At the upper price band of ₹208, the estimated listing price may be around ₹248, implying a potential listing gain of approximately 19%.
Note: GMP is unofficial and changes daily depending on market sentiment.
Avience Biomedicals Financial Performance
(₹ Crore)
Financial Highlights
Revenue nearly doubled from FY24 to FY25.
PAT increased significantly to ₹7.23 crore.
Strong net worth growth.
Healthy operating cash flow.
Expansion funded partly through borrowings.
Key Performance Indicators (KPIs)
The valuation appears reasonable compared to many SME IPOs, supported by strong profitability metrics.
Objectives of the Issue
The company intends to utilize the IPO proceeds for:
1. New Manufacturing Facility
Investment of approximately ₹15.96 crore for setting up a manufacturing unit at the Medical Device Park, YEIDA, Gautam Buddha Nagar, Uttar Pradesh.
2. Working Capital Requirements
Around ₹8.25 crore will be used to support operational growth.
3. General Corporate Purposes
These investments are expected to enhance manufacturing capacity and support future growth.
Strengths of Avience Biomedicals
Diversified Product Portfolio
The company offers multiple diagnostic products, reducing dependence on a single segment.
Strong Industry Experience
Management possesses significant expertise in biotechnology and medical diagnostics.
Growing Distribution Network
Avience has established a strong domestic presence and is expanding internationally.
Cost-Effective Solutions
Affordable diagnostic products provide a competitive advantage.
Strong Profitability
Healthy margins and return ratios indicate efficient operations.
Risks and Weaknesses
Dependence on Suppliers
Supply chain disruptions could affect operations.
High Research & Development Costs
Continuous innovation requires substantial investments.
Intense Competition
The diagnostics industry is highly competitive with established players.
Regulatory Risks
Medical device businesses are subject to strict regulatory compliance.
Rising Debt Levels
Borrowings have increased over the years, which investors should monitor.
Avience Biomedicals IPO Lot Size
Promoters of Avience Biomedicals
The promoters of the company are:
Mr. Dharam Deo Choudhary
Mr. Ram Nagina Choudhary
Mr. Janardan Pal
Ms. Deepa Choudhary
Shareholding Pattern
Avience Biomedicals IPO Review
Positive Factors
✔ Strong profitability and margins.
✔ Reasonable valuation with P/E of 10.91x.
✔ Presence in the fast-growing diagnostics and biotechnology sector.
✔ Capacity expansion through a new manufacturing facility.
✔ Healthy return ratios (ROE 38.64%).
Concerns
✘ SME IPO with relatively lower liquidity.
✘ Dependence on suppliers.
✘ Increasing debt levels.
✘ Competitive industry and regulatory challenges.
Should You Apply for Avience Biomedicals IPO?
Avience Biomedicals operates in a promising healthcare segment and has demonstrated robust profitability, healthy margins, and efficient capital utilization. The IPO is priced at a reasonable valuation of around 10.91x P/E, making it attractive compared to many SME offerings.
However, investors should consider the risks associated with SME listings, rising debt, and intense competition.
Verdict: Subscribe for Long-Term and Listing Gains Perspective
Investors with moderate risk appetite looking for exposure to the diagnostics and healthcare sector may consider applying to the Avience Biomedicals IPO, while keeping SME volatility in mind.
Frequently Asked Questions (FAQs)
What is the Avience Biomedicals IPO date?
The IPO opens on 18 June 2026 and closes on 22 June 2026.
What is the price band of Avience Biomedicals IPO?
The price band is ₹196 to ₹208 per share.
What is the lot size?
The lot size is 600 shares, and retail investors need to apply for a minimum of 2 lots.
What is Avience Biomedicals IPO GMP today?
The latest GMP is around ₹40, subject to market changes.
Where will the IPO be listed?
The shares are proposed to be listed on the NSE SME platform.
Should investors apply?
Considering strong financial performance, reasonable valuation, and growth prospects, the IPO appears suitable for investors with a medium-to-high risk appetite.
Post a Comment